Merlintrader
Trading Pub
Message board
Merlintrader: Welcome to the new biotech dashboard!
ChartsWatcherDiscount code: SAVE10
Main chart S&P 500
News feed
US markets
Ticker news
My watchlist saved in this browser
Loading watchlist…
Biotech Catalyst Lookup
Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.
Automatically generated AI snapshot
Enter a ticker to receive a snapshot generated by artificial intelligence using web sources. Responses are not individually checked by a person before they are displayed.
Dates, events and sources may be incomplete, incorrect or out of date. Check the information against official company releases, SEC filings, FDA documents or ClinicalTrials.gov. Estimated dates are not firm deadlines.
For information and education only. Not investment advice or a recommendation to buy or sell securities.
Read the full disclaimerRecently viewed catalysts
ARWRClinical
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
Oral presentations at the American Heart Association (AHA) Scientific Sessions 2026: first-in-human Phase 1/2a results of ARO-DIMER-PA and a pooled analysis of Phase 3 SHASTA-3 and SHASTA-4 plozasiran data
2026-11-07
CLGNCatalyst
CollPlant Biotechnologies Ltd. (Nasdaq: CLGN)
Extraordinary general meeting of shareholders to vote on changing the company name to OptiPhi Computing Ltd.
2026-11-24
ADCTClinical
ADC Therapeutics SA (NYSE: ADCT)
Full results from the Phase 3 LOTIS-5 study of ZYNLONTA plus rituximab vs R-GemOx in r/r DLBCL, scheduled for oral presentation at the 68th ASH Annual Meeting (New Orleans, December 12-15, 2026)
2026-12-14
OSCRData readout
Oscar Health, Inc.
HealthCare.gov Marketplace enrollment deadline for January 1, 2027 coverage
2026-12-15
CORTPDUFA
Corcept Therapeutics Incorporated (NASDAQ: CORT)
FDA target action date (PDUFA) for relacorilant NDA resubmission in hypercortisolism (Cushing's syndrome)
2026-12-17
GILDPDUFA
Gilead Sciences, Inc. (GILD)
FDA decision on the BLA for anito-cel (anitocabtagene autoleucel) in fourth-line relapsed or refractory multiple myeloma
2026-12-23
CMPSRegulatory
Compass Pathways plc (CMPS)
Completion and submission of the final rolling New Drug Application (NDA) for COMP360 psilocybin in treatment-resistant depression (TRD)
Within two weeks of 2026-11-03 (company-stated period; no exact filing day announced)
CGTXClinical
Cognition Therapeutics, Inc. (NASDAQ: CGTX)
Top-line results from the Phase 2 START study of zervimesine (CT1812) in mild cognitive impairment and early Alzheimer's disease
second half of 2027
FDA Calendar next 30 days
Loading catalysts…
Dates may change. PDUFA goal dates, FDA meetings and other catalyst dates come from company disclosures and public sources and can change at any time without notice: the FDA may act before or after a goal date, extend a review or issue a Complete Response Letter, and companies may delay, move or withdraw events. Always check the latest SEC filings and company press releases.
Biotech catalysts / clinical trials with estimated timing
Company guidance
Loading estimates…
Trial primary completions
Loading trials…
Floating dates – must be reconfirmed. Everything in this box is an estimate, not a confirmed date. Company guidance (“Q4”, “late 2026”, “November”) and ClinicalTrials.gov estimated primary completion dates change often and frequently slip by months. Primary completion is when the last patient’s primary-endpoint data is collected: topline results, if announced at all, usually come weeks or months later. Do not rely on these dates without reconfirming them on the latest SEC filings, company press releases and the trial record.
Latest from Merlintrader
Loading the latest content…
Weekly calendar events
Loading this week’s events…
Economic / macro calendar
Legal disclaimer
Important notice: the information on this page is for educational and informational purposes only. It does not constitute investment advice, a personalized recommendation, or an offer or solicitation to buy or sell any security. Merlintrader is not a registered investment adviser or broker-dealer (SEC) and is not an investment firm authorized by CONSOB under Italian Legislative Decree 58/1998 (TUF).
Risks: investing in securities, especially small caps and biotech stocks exposed to binary events (FDA decisions, clinical data), carries a high risk of losing your capital. Past performance is not indicative of future results. Quotes, news feeds and third-party widgets may be delayed or contain errors.
Catalyst dates: PDUFA goal dates, FDA advisory committee meetings, clinical data readouts, conference presentations and other catalyst dates shown on this page (calendar, heatmap and articles) are based on company disclosures and public sources available at the time of publication. They are not guaranteed and may be changed, delayed, brought forward or cancelled at any time without notice. The FDA may act before or after a goal date, extend a review (for example by three months after a major amendment) or issue a Complete Response Letter. Ranges such as “Q4”, “late 2026” or “by year-end” are company estimates, not confirmed dates. Merlintrader does not guarantee the accuracy, completeness or timeliness of any date.
Do your own research: always verify information against primary sources (SEC filings, company press releases, FDA, ClinicalTrials.gov) and consult a licensed financial advisor before making any investment decision.
Liability: the owner and operators of this website accept no liability for any loss or damage arising from the use of the information published here.
